TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Vivani Medical ( (VANI) ).
On October 26, 2025, Vivani Medical, Inc. announced the pricing of a registered direct offering and a concurrent private placement of its common stock, expected to raise approximately $15.7 million in gross proceeds. The funds will be used for ongoing research, clinical development, and general corporate purposes, with ThinkEquity acting as the sole placement agent for the registered offering.
The most recent analyst rating on (VANI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform. The company focuses on creating GLP-1 based implants for metabolic diseases, including obesity and type 2 diabetes, aiming to improve medication adherence and patient tolerance.
Average Trading Volume: 207,349
Technical Sentiment Signal: Buy
Current Market Cap: $95.98M
Find detailed analytics on VANI stock on TipRanks’ Stock Analysis page.